Nicole A. Kratochwil
0000-0002-2149-4375
Publication & Citation Trends
Publications
0 total
First-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancers
Cited by 0
Semantic Scholar
Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid Tumors
Cited by 0
Semantic Scholar
Abstract 5606: The novel brain-penetrant paradox breaker BRAF inhibitor RG6344 manifests exceptional activity in BRAF mutant colorectal cancers
Cited by 1
Semantic Scholar
Preliminary safety, pharmacokinetics, and clinical activity of RG6344 in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC).
Cited by 2
Semantic Scholar
Mosperafenib, a novel paradox breaker BRAF inhibitor with potent preclinical activity in BRAF mutated colorectal cancer.
Cited by 1
Semantic Scholar
Abstract CT017: A phase I study evaluating safety, pharmacokinetics, and clinical activity of the novel, paradox breaker BRAF inhibitor RG6344 in patients with BRAF V600-mutant solid tumors
Cited by 0
Semantic Scholar
Research Topics
Melanoma and MAPK Pathways
(17)
Metal complexes synthesis and properties
(16)
Genetic Mapping and Diversity in Plants and Animals
(13)
Receptor Mechanisms and Signaling
(12)
Protein Kinase Regulation and GTPase Signaling
(9)
Affiliations
Roche (Switzerland)
Pfizer (United States)
Roche (China)
University of Regensburg
University of Edinburgh